Background: The 3'UTR region plays a crucial role in regulating gene expression at posttranscriptional levels. Any changes in sequence in this region can cause numerous pathologies and can also lead to tumour development. The most common changes reported in the CDKN2A gene are the 148Ala/Thr in exon 2 and 500C>G and 540C>T in the 3'UTR region. They are suspected of having a great impact on cancer progression. Since the role of these sequence variants in the Polish population in the development of melanoma has not been confirmed, the importance of 3'UTR polymorphisms in the regulation of gene expression was tested.

Material and methods: First, genetic analysis in a group of 285 melanoma patients was performed and the obtained results were correlated with the clinical course of melanoma. Then vectors carrying 3'UTR sequence variants were prepared and the level expression of the reported gene was measured.

Results: Within this study no correlation between the presence of 148Ala/Thr polymorphism and cancer in the family was observed. There was a correlation between the presence of this polymorphism and breast cancer and melanoma in the same patient. There was no correlation between 500C>G polymorphism and tumour localization, age of diagnosis, and type of cancer in patients’ family, but a correlation between the percentage of patients dying and the 500C>G variant was observed.

Conclusion: The results of functional tests indicated that the presence of polymorphism in the 3'UTR region of the CDKN2A gene resulted in changes in the level of reporter gene expression.

Keywords: melanoma, CDKN2A, 3'UTR, polymorphisms.

Contemp Oncol (Pozn) 2015; 19 (4): 276–279 DOI: 10.5114/wo.2015.54227

Analysis of sequence variants in the 3’UTR of CDKN2A gene in melanoma patients

Anna Przybyła1, Katarzyna Lamperska2, Andrzej Mackiewicz1

1Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland
2Laboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland

Introduction

Cutaneous melanoma has an increasing incidence rate worldwide [1]. The aetiology of melanoma, like other cancers, is heterogeneous and involves environmental factors and genetic predispositions [2]. It has been demonstrated that the inactivation or mutations of certain genes lead to tumour development. One of the best known of these genes is CDKN2A (OMIM*600160). It was identified as the first high-penetrance melanoma susceptibility gene linked with family history of melanoma, young age of onset, and multiple primary tumours [3–5]. The CDKN2A gene is located on chromosome 9p21 and, what is very interesting, encodes two different proteins: p16 and p14ARF, which are involved in cell cycle regulation [6]. In the Polish population, mutations in the CDKN2A gene are very rare [7, 8]. Thus, more attention has been focused on polymorphisms and non-coding regions of CDKN2A that play a significant role in regulation of gene expression [9].

The messenger RNA 3'-untranslated region (3'UTR) is emerging as critically important in regulating gene expression at posttranscriptional levels. Posttranscriptional events comprise pre-mRNA processing, nucleo-cytoplasmic export, mRNA localization, mRNA stabilization, and translational regulation [10]. Abnormalities in any of these important processes can lead to a number of diseases, including the development of cancer [11]. The most commonly reported changes in non-coding regions of the gene CDKN2A, suspected of having an impact on risk [12] and progressive disease [13], are polymorphisms 500C>G and 540C>T in episode 3'UTR. It is believed that substitutions 540C>T can affect the transport, stability, and translation of p16 mRNA, and consequently, the function of p16 and p14ARF. It is said that there is a correlation between the presence of changes in 3'UTR and a shorter survival time after melanoma remission [14]. In the Polish population the incidence of these two polymorphisms and determination their role in the origin and course of the disease are still unclear.

In these circumstances we decided first of all to perform the genetic analysis of the 3'UTR region of CDKN2A gene in a group of 285 melanoma patients, and to correlate those results with the clinical course of melanoma such as: age of first diagnosis, tumour localization, survival rate, age of death, coexistence of another type of cancer, and familial history of disease (data published in 2007) [15]. The second step of our experiments was to carry out a functional analysis in vitro in order to assess whether the presence of polymorphisms in the 3'UTR region have any influence on the CDKN2A level expression.

Material and methods

Blood samples and clinical features of the disease were collected from 285 melanoma patients.
For functional analysis the melanoma cell lines MICH-2, MeWo, WM35, WM902B, and HSK MEC.1 (human skin microvascular endothelial cells) were used. Cells were maintained in DMEM (Gibco Invitrogen) medium supplemented with 10% FBS and 1% antibiotics. After 4 days, the cell cultures were washed with RPMI medium containing 1% antibiotics, trypsinised, and counted. The cells were then seeded in 24-well plates at a density of 5 x 10^4 cells per well and grown at 37°C in an atmosphere of 95% air – 5% CO₂ in RPMI supplemented with 10% FBS (Gibco Invitrogen) medium supplemented with 10% FBS.

The study was approved by Regional Bioethics Committee (RBC) in Poznan, Poland and written informed consent was obtained from all melanoma patients and healthy volunteers involved in the study. The patients records was anonymized and de-identified prior to analysis.

**DNA isolation.** DNA was isolated from whole blood samples or from PBMC stored in liquid nitrogen, using a Wizard Genomic Extraction Kit (Promega, USA) according to the manufacturer’s protocol.

**PCR-SSCP analysis.** The following set of primers for the 3'UTR analysis were used: (1) 5' CCg gTA ggg ACg gCA gAg gA 3', (2) 5' CTg TAg gAC CCT Cgg TgA CTg ATg 3', (3) 5' CTg TAg ACg CCT Cgg TgA ATg 3', (4) 5' gAC ATC CCC gAT TgA AAg AAC 3', (5) 5' TTT ACg gTA gTg ggg gAA gg 3', (6) 5' gTC Ctg CCT TTT AAC gTA gA 3', (7) 5' CCT Gag CCT CCC TAg TTC AC 3', (8) 5' Ctg Cct AAC gAg CgC ACA TTC AT 3', (9) 5' TTT gTA gTg gAT gAA AAg AAA TT 3'. Primers were labelled to the 5' end with [α-32P]ATP (3000Ci/mmole, Amersham). The reaction volume for PCR was 5 µl and included 1xPCR buffer, 1.5 mM MgCl₂, 0.2 mM dNTPs, 1.5 µM of appropriate primers, 0.25 U of aTaq DNA polymerase (Promega), and 50 ng of genomic DNA. Standard PCR conditions were applied, with annealing temperature 58°C for all primer sets. Electrophoresis was carried out at room temperature at 25 W. Gels were transferred onto Whatman 3 MM paper, dried, and autoradiographed.

**Sequencing analysis.** Sequencing reactions were performed using the /mol DNA Cycle Sequencing System (Promega) with the same set of primers that were used in the initial PCR amplification. Statistical analysis was performed using Shapiro-Wilk and Lilliefors tests and then Student's t-test, χ² test with Yate's modifications, and Fish-er's exact test. Statistical significance of clinical features was tested by Mann-Whitney test.

**Cell lines and culture conditions:** For functional analysis the melanoma cell lines MICH-2, MeWo, WM35, WM902B, and HSK MEC.1 (human skin microvascular endothelial cells) were used. Cells were maintained in DMEM (Gibco Invitrogen) medium supplemented with 10% FBS (Gibco Invitrogen) and 80 µg/ml gentamycin (KVRKa). Cells were grown at 37°C in an atmosphere of 95% air – 5% CO₂.

**Plasmids:** To prepare the 500G/C and 540C/T variants of 3'UTR CDKN2A gene, a pair of complementary 24 nt primers containing the desired mutations was used: (1) 5' gTT CTA Gac ATC CCC gAT TgA AAg AAC 3', (2) 5' CTg ggA TCC TTT gTA gTg gAT gAA Tg 3', (3) 5' TCT ggg gAA CCT Cgg gA 3', (4) 5' SAg TTT CCC gAg gTT TCT CAg A 3', (5) 5' SAg CTC CAg ggC TAC AAC gTg gCC CgC 3', (6) 5' gAg ggg gTA gTg TgA gAC gAc CAC ATg 3'. In the next step, products of PCR reactions were cloned into the phRL-CMV vector (Promega) and sequenced using the DNA Cycle Sequencing System (Promega) with the same set of primers that were used in the PCR amplification. Sequencing reactions were performed using an annealing temperature 58°C for all primer sets.

**Luciferase assays in cell lines.** A total of 3 x 10⁴ cells were seeded in six-well plates 24 hours before transfection. Cells were transfected at ~90% confluence using FuGene HD transfection reagents (Roche Diagnostics), according to the manufacturer’s instructions. Cells were harvested 24 hours after transfection, and luciferase assays were carried out using reagents of the Dual Luciferase Reporter Assays System (Promega). The presented results of measurements are the average of three independent repeats of each experiment. Statistical analysis was performed using GraphPad InStat v3.05 (GraphPad Software). The association of genotype and luciferase activity was evaluated by one-way ANOVA test and post-hoc Student-Newman-Keuls test.

**Results**

**Analysis of clinical data**

Analysis of the clinical data in the group of 285 patients was performed and presented in the following publication: Lamperska K., et al. 2007 [15].

**PCR-SSCP analysis**

Analysis showed the 500 C/G variant in 62 cases and 148 Ala/Thr polymorphism in seven cases. Both changes together were present in five cases, and the correlation between the variants 500 C/G and 148 Ala/Thr was statistically significant (p = 0.0066). Patients with multiple cancers including melanoma did not show polymorphisms in the CDKN2A gene. The presence of mutations in the BRCA1 gene, characteristic for the Polish population in all patients with breast cancer as the second, concomitant with melanoma cancer, were investigated [16]. No changes in BRCA1 were found. Polymorphism 500C/G was found in nine patients having cancers in the family, but no correlation with the type of cancer was established. 148 Ala/Thr was present in one patient with a family cancer history, together with the 500 C/G variant. Since 148 Ala/Thr was recognised mostly in DNA from patients with no cancer history in the family, correlation analysis between the variant and the type of cancer in the family was not performed. Polymorphism 500 C/G was found in 26 living persons and 37 dead. The correlation between the percentage of dead patients and the 500 C/G polymorphism was found to be statistically significant (p = 0.0252) (Table 1). No correlation was observed for 148 Ala/Thr (p = 0.5608) alone, or for the 500 C/G plus 148 Ala/Thr together (p = 0.0509). The median age of diagnosis of all the patients was 47 years, while for the carriers of the 500 C/G variant it was 50 years. No correlation between the age of diagnosis and the presence of the 500 C/G variant was 50 years. No correlation was found for carriers of the 148 Ala/Thr polymorphism and the age of melanoma diagnosis (p = 0.2358).

**Functional analysis**

Three vectors carrying the three most common sequence variants (500C>G, 540C>T, and variant without mutation – wild type) together with luciferase reporter gene were constructed and used for tumour cell transfections. In all performed experiments differences in reporter gene expression were found.

**Table 1. CDKN2A polymorphisms and number of death and survivals**

<table>
<thead>
<tr>
<th>Variable</th>
<th>0 (death)</th>
<th>1 (survival)</th>
<th>χ² (value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>500C&gt;G</td>
<td>37</td>
<td>26</td>
<td>Fisher p = 0.0252*</td>
</tr>
<tr>
<td>500C&gt;G + 148</td>
<td>37</td>
<td>28</td>
<td>Fisher p = 0.0509*</td>
</tr>
<tr>
<td>Ala/Thr</td>
<td>95</td>
<td>127</td>
<td>Fisher p = 0.0352*</td>
</tr>
</tbody>
</table>
depending on the 3'UTR variant were observed. In our experiments the value of the luminescence emitted by cells transfected with the 3'UTR-wt variant was equated to 1. In HSK MEC.1, WM 902B, WM 35, and MeWo cells 3'UTR-500C>G and 3'UTR-540C>T variants led to a reduction in reporter activity. In the HSK MEC.1 cell line, variant 3'UTR-500C>G, a 2.9-times lower expression of the reporter protein in comparison to the variant 3'UTR-wt ($p = 0.0149$) and a 10-times lower expression of the variant 3'UTR-540C>T ($p = 0.0006$) was observed. These differences were statistically significant.

The WM 902B showed 2.2-times lower activity of luciferase for variant 3'UTR-500C>G compared to the 3'UTR-wt ($p = 0.1690$) and 8.6-times lower for variant 3'UTR-540C>T ($p = 0.0013$), and the difference was statistically significant.

In WM 35 cells variant 3'UTR-500C>G shown 1.3-times lower reporter activity in relation to the 3'UTR-wt ($p = 0.0185$ and $p = 0.0014$, respectively). This difference was statistically significant.

In another melanoma cell line, MeWo, expression of reporter gene in case of 3'UTR-500C>G and 3'UTR-540C>T was 2.1- and 18.3-times lower than the wild type variant ($p = 0.3499$ and $p = 0.3854$, respectively).

We noticed that in all melanoma cell lines the level of reported gene expression was different in the case of sequence variants relative to the wild type.

Discussion

The CDKN2A gene is one of the first genes thoroughly analysed in the last decade, due to the high (90%) percentage of mutations found in melanoma cell lines [17]. Somatic mutations are found in varying proportion of cases and on both sporadic [18] or hereditary melanoma [19]. Most mutations associated with the disease occur in exon 1α and exon 2, affecting the p16 protein [20]. In the Polish population hereditary mutations in the CDKN2A gene are very rare [7], and the polymorphisms are detected with higher incidence in melanoma patients compared to healthy volunteers.

The most common polymorphism recorded in the coding region of CDKN2A is 148Ala/Thr in exon 2, which is significantly more frequent in patients with melanoma than in controls [21]. It was initially described as a common polymorphism, without major effects on p16 function [22]. However, additional reports have implicated CDKN2A 148Ala/Thr as a melanoma susceptibility variant among MPM patients. In Poland this polymorphism was associated with melanoma risk (regardless of family history) [7]. Within our study no correlation between the presence of 148Ala/Thr polymor-

![Fig. 1. Impact of the CDKN2A 3'UTR sequence variant on luciferase activity in melanoma cell lines: (A) HSK MEC.1 (human skin microvascular endothelial cells), (B) WM 902B, (C) WM 35, (D) MeWo, and (E) Mich-2](image-url)
Analysis of sequence variants in the 3’UTR of CDKN2A gene in melanoma patients

The project was supported by grant N N401 063637 funded by the Ministry of Science and Higher Education. The authors declare no conflict of interest.

References


Address for correspondence
Anna Przybyta
Department of Cancer Immunology
Chair of Medical Biotechnology
Poznan University of Medical Sciences
Poznan, Poland
email: przybka@wp.pl

Submitted: 7.06.2015
Accepted: 20.08.2015